SYNCOM
FORMULATIONS (INDIA) LIMITED
A WHO-GMP & ISO 9001:2015 Certified Company
CIN No.: L24239MH1988PLC047759
Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai - 400 093, INDIA, Tel.: +91-22-42824400, Email: sfil87@sfil.in
Corp. Off. : 207, Saket Nagar, Indore - 452 018, INDIA. Tel. : +91-731-2560458 / 2700458, Email : info@sfil.in, Website : www.sfil.in
Works : 256-257, Sector-I, Pithampur, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: +91-7292-403122 / 407039, Email : info@sfil.in

SYNCOM/SE/2026-27 **11th August, 2026**

Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2026.

Dear Sir/Ma'am,

This is in continuation of our letter no. **SYNCOM/SE/2026-27** dated 6th August, 2026 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2026, in PDF Format, which were also approved and recommended by the Audit Committee and further approved by the Board of Directors at their meeting held on Tuesday, 11th August 2026.

The Board Meeting was commenced at 4:00 P.M. and concluded at 04:45 P.M.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company.

You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record.

Thanking You
Yours Faithfully
For, SYNCOM FORMULATIONS (INDIA) LIMITED

Vaishali Agrawal
Digitally signed by Vaishali Agrawal
Date: 2026.08.11 17:23:08 +05'30'

CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER
Encl: *Unaudited Standalone and Consolidated Financial Results and Limited Review Report.*

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

Rs. In Lakhs except EPS

S. No.	Particulars	Quarter Ended			Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	12465.95	13400.03	11654.69	48657.28
2	Other Income	781.80	1422.83	601.97	3096.63
3	**Total Income (1 + 2)**	**13247.75**	**14822.86**	**12256.66**	**51753.91**
4	**EXPENSES**				
	(a) Cost of materials consumed	5877.61	6744.83	5961.30	22093.67
	(b) Purchases of Stock-in-Trade	1733.09	2015.34	1561.93	6670.04
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(1036.11)	(465.11)	(616.39)	(390.11)
	(d) Employee benefits expense	1716.67	1694.73	1595.44	6708.51
	(e) Finance costs	23.04	36.71	23.74	110.48
	(f) Depreciation and amortization expense	154.03	248.23	134.00	653.23
	(g) Other expenses	1588.54	1261.58	1574.94	5859.27
	Total expenses (4)	**10056.87**	**11536.31**	**10234.96**	**41705.09**
5	**Profit/(loss) before exceptional items and tax (3- 4)**	**3190.88**	**3286.55**	**2021.70**	**10048.82**
6	Exceptional Items	0.00	(0.44)	4.13	3.69
7	**Profit/(loss) before tax (5 - 6)**	**3190.88**	**3286.11**	**2025.83**	**10052.51**
8	Tax expense:				
	(1) Current tax	719.07	716.57	431.60	2270.29
	(2) Deferred tax	12.89	112.12	21.30	181.42
9	**Profit (Loss) for the period from continuing operations (7-8)**	**2458.92**	**2457.42**	**1572.93**	**7600.80**
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00
13	**Profit/(loss) for the period (9 + 12)**	**2458.92**	**2457.42**	**1572.93**	**7600.80**
14	Other Comprehensive Income				
	A(*i*)Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(*ii*) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (*i*) Items that will be reclassified to profit or loss	381.87	(995.17)	403.84	(360.73)
	(*ii*) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
15	**Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)**	**2840.79**	**1462.25**	**1976.77**	**7240.07**
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	0.00	0.00	0.00	31830.45
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.26	0.26	0.17	0.81
	(2) Diluted	0.26	0.26	0.17	0.81
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.26	0.26	0.17	0.81
	(2) Diluted	0.26	0.26	0.17	0.81

Place: Indore

Date: 11.08.2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

DIN: 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

S. No.	Particulars	Quarter Ended			Year to date Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	**Segment Revenue**				
	a) Pharmaceuticals Drugs & Formulations	13,135.78	14,726.34	12,062.52	51,274.35
	b) Trading of Commodities	27.84	4.03	104.56	110.03
	c) Renting of Property	84.13	92.49	89.58	369.53
	Total Segment Revenue	**13,247.75**	**14,822.86**	**12,256.66**	**51,753.91**
	Less: Inter Segment Revenue	-	-		-
	Total Income	**13,247.75**	**14,822.86**	**12,256.66**	**51,753.91**
2	**Segment Results Profit(+)/Loss(-) before tax and interest from each segment**				
	a) Pharmaceuticals Drugs & Formulations	3,134.50	3,286.18	1,960.52	9,865.61
	b) Trading of Commodities	1.99	(4.35)	1.35	(2.63)
	c) Renting of Property	77.43	40.99	83.57	300.01
	Total Profit before tax and Interest	**3,213.92**	**3,322.82**	**2,045.44**	**10,162.99**
	Less: i) Interest	23.04	36.71	23.74	110.48
	ii) Other Un-allocable Expenditure	-	-		-
	Profit before tax	**3,190.88**	**3,286.11**	**2,021.70**	**10,052.51**
3	**(Segment Asset-Segment Liabilities)**				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	45,500.08	43,517.55	39,302.09	43,517.55
	b) Trading of Commodities	4.56	66.51	259.18	66.51
	c) Renting of Property	9,257.24	9,342.00	4,733.44	9,342.00
	Total Segment Asset	**54,761.88**	**52,926.06**	**44,294.71**	**52,926.06**
	Un-allocable Assets	-	-		-
	Net Segment Asset	**54,761.88**	**52,926.06**	**44,294.71**	**52,926.06**
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	10,563.27	11,523.42	8,185.83	11,523.42
	b) Trading of Commodities	12.50	4.12	8.36	4.12
	c) Renting of Property	284.17	168.07	133.36	168.07
	Total Segment Liabilities	**10,859.94**	**11,695.61**	**8,327.55**	**11,695.61**
	Un-allocable Liabilities	-	-	-	-
	Net Segment Liabilities	**10,859.94**	**11,695.61**	**8,327.55**	**11,695.61**

Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11/08/2026

2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2026. The report does not have any impact on the above results and notes which needs explanation.

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

6 During the current period, the Company has corrected its method of calculating Earnings Per Share (EPS). In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previouly reported and restated are as below

Previously Reported EPS (TCI)	Quarter Ended			Year Ended
	30/06/2026	31/03/2026	30/06/2025	31/03/2026
	Unaudited	Audited	Audited	Audited
Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	NA	NA	0.21	NA
(2) Diluted	NA	NA	0.21	NA
Restated EPS (PAT))				
Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	0.26	0.26	0.17	0.81
(2) Diluted	0.26	0.26	0.17	0.81

Place: Indore
Date: 11.08.2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
DIN: 02359461

SANJAY MEHTA & ASSOCIATES
Chartered Accountants

338, Saket Nagar, Indore - 452 018 (M.P.)
Phone : 0731-2563625, 4274391, 94250 62964
E-mail : office@smaonline.in

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Three Months ended 30th June, 2026 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company"),** for the period ended June, 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", *issued* by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates
Chartered Accountants
FRN: 011524C

SANJAY MEHTA & ASSOCIATES INDORE

Place: Indore
Date: 11th August, 2026

CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 26079452ODNWFM4120

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

Rs. In Lacs except EPS

S. No.	Particulars	Quarter Ended			Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	12,552.64	13,541.18	11,690.17	48,917.15
2	Other Income	782.94	1,455.38	603.47	3,133.99
3	**Total Income (1 + 2)**	**13,335.58**	**14,996.56**	**12,293.64**	**52,051.14**
4	**EXPENSES**				
	(a) Cost of materials consumed	5,877.62	6,744.84	5,961.30	22,093.68
	(b) Purchases of Stock-in-Trade	1,824.49	2,054.53	1,568.13	6,722.87
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(1,115.72)	(468.21)	(612.48)	(389.30)
	(d) Employee benefits expense	1,716.67	1,694.73	1,595.44	6,708.51
	(e) Finance costs	24.45	37.59	25.08	115.50
	(f) Depreciation and amortization expense	154.03	248.23	134.00	653.23
	(g) Other expenses	1,628.82	1,314.15	1,597.06	6,038.39
	Total expenses (4)	**10,110.36**	**11,625.86**	**10,268.53**	**41,942.88**
5	**Profit/(loss) before exceptional items and tax (3- 4)**	**3,225.22**	**3,370.70**	**2,025.11**	**10,108.26**
6	Exceptional Items	-	(0.44)	4.13	3.69
7	**Profit/(loss) before tax (5 - 6)**	**3,225.22**	**3,370.26**	**2,029.24**	**10,111.95**
8	Tax expense:				
	(1) Current tax	727.65	740.70	432.50	2,286.73
	(2) Deferred tax	12.89	112.12	21.30	181.42
9	**Profit (Loss) for the period from continuing operations (7-8)**	**2,484.68**	**2,517.44**	**1,575.44**	**7,643.80**
10	Profit/(loss) from discontinued operations	-	-	-	-
11	Tax expense of discontinued operations	-	-	-	-
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	-	-	-	-
13	**Profit/(loss) for the period (9 + 12)**	**2,484.68**	**2,517.44**	**1,575.44**	**7,643.80**
14	Other Comprehensive Income				
	A(*i*)Items that will not be reclassified to profit or loss	-	-	-	-
	(*ii*) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (*i*) Items that will be reclassified to profit or loss	381.87	(995.17)	403.84	(360.73)
	(*ii*) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
15	**Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)**	**2,866.55**	**1,522.27**	**1,979.28**	**7,283.07**
16	Paid up Share Capital of the Company (Face Value 1/-)	9,400.00	9,400.00	9,400.00	9,400.00
17	Reserves excluding revaluation reserves			-	32,098.83
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.26	0.27	0.17	0.81
	(2) Diluted	0.26	0.27	0.17	0.81
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.26	0.27	0.17	0.81
	(2) Diluted	0.26	0.27	0.17	0.81

Place: Indore
Date: 11.08.2026

For, Syncom Formulations (India) Limited

SYNCOM FORMULATIONS (INDIA) LTD. *

Ankit

Ankit Kedarmal Bankda
Chairman & Wholetime Director
DIN: 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS THE QUARTER ENDED 30TH JUNE 2026

Rs. In Lacs except EPS

S. No.	Particulars	Quarter Ended			Year to date Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	**Segment Revenue**				
	a) Pharmaceuticals Drugs & Formulations	13223.61	14900.49	12,099.95	51,573.38
	b) Trading of Commodities	27.84	4.03	104.56	110.03
	c) Renting of Property	84.13	92.04	89.13	367.73
	Total Segment Revenue	**13,335.58**	**14,996.56**	**12,293.64**	**52,051.14**
	Less: Inter Segment Revenue				-
	Total Income	13,335.58	14,996.56	12,293.64	52,051.14
2	**Segment Results Profit(+)/Loss(-) before tax and interest from each segment**				
	a) Pharmaceuticals Drugs & Formulations	3170.25	3371.66	1,969.85	9,931.87
	b) Trading of Commodities	1.99	-4.35	1.35	(2.63)
	c) Renting of Property	77.43	40.54	83.12	298.21
	Total Profit before tax and Interest	**3,249.67**	**3,407.85**	**2,054.32**	**10,227.45**
	Less: i) Interest	24.45	37.59	25.08	115.50
	ii) Other Un-allocable Expenditure				-
	Profit before tax	3,225.22	3,370.26	2,029.24	10,111.95
3	**(Segment Asset-Segment Liabilities)**				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	46037.15	43976.01	39,780.77	43,976.01
	b) Trading of Commodities	4.56	66.51	259.18	66.51
	c) Renting of Property	9257.24	9342.00	4,733.44	9,342.00
	Total Segment Asset	**55,298.95**	**53,384.52**	**44,773.39**	**53,384.52**
	Un-allocable Assets				-
	Net Segment Asset	**55,298.95**	**53,384.52**	**44,773.39**	**53,384.52**
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	10789.14	11713.50	8,436.63	11,713.50
	b) Trading of Commodities	12.50	4.12	8.36	4.12
	c) Renting of Property	284.16	168.07	133.36	168.07
	Total Segment Liabilities	**11,085.80**	**11,885.69**	**8,578.35**	**11,885.69**
	Un-allocable Liabilities			-	-
	Net Segment Liabilities	**11,085.80**	**11,885.69**	**8,578.35**	**11,885.69**

Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11.08.2026

2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2026. The report does not have any impact on the above results and notes which needs explanation.

5 The Company currently have 3 (Three) Wholly owned Subsidiaries namely Synmex Pharma Pvt Ltd , Vincit Pharma Pvt Limited and Sante Biotech Pvt Ltd

6 During the current period, the Company has corrected its method of calculating Earnings Per Share (EPS). In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previously reported and restated are as below

Previously Reported EPS (TCI)	Quarter Ended			Year Ended
	30/06/2026	31/03/2026	30/06/2025	31/03/2026
	Unaudited	Audited	Unaudited	Audited
Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	NA	NA	0.21	NA
(2) Diluted	NA	NA	0.21	NA
Restated EPS (PAT))				
Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	0.26	0.27	0.17	0.81
(2) Diluted	0.26	0.27	0.17	0.81

Place: Indore
Date: 11.08.2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
DIN: 02359461

SANJAY MEHTA & ASSOCIATES
Chartered Accountants

338, Saket Nagar, Indore - 452 018 (M.P.)
Phone : 0731-2563625, 4274391, 94250 62964
E-mail : office@smaonline.in

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Three Months ended 30th June, 2026 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended June 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued* by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entity:

S. No.	Name of the Company	Relationship with the Holding Company
1.	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vircit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary

SANJAY MEHTA & ASSOCIATES INDORE

5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates
Chartered Accountants
FRN: 011524C

SANJAY MEHTA & ASSOCIATES INDORE

Place: Indore
Date: 11th August, 2026

CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 26079452LQCPSD2909